What's new? Log in Free sign up

Chromadex (CDXC) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $5 price target.

Recap: ChromaDex Q1 Earnings

ChromaDex Q1 EPS $(0.03) Beats $(0.05) Estimate, Sales $22.56M Beat $19.32M Estimate

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 72.73 percent increase over losses of $(0.11) per share from the same

Earnings Scheduled For May 10, 2023

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.

HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $5

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $5.5 to $5.

Press releases

From Benzinga Pro

ChromaDex to Participate in the LD Micro Invitational XIII

ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in

ChromaDex Corporation Reports First Quarter 2023 Financial Results

Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.